1,3-二氮杂螺[4,5/4]癸/壬-1-烯-4-酮类衍生物的合成及其生物活性

目的 设计合成新型非肽类血管紧张素Ⅱ(AⅡ)受体拮抗剂，评价其抑制AⅡ诱发的兔主动脉收缩反应的生物活性。方法 以1，3-二氮杂螺[4，5／4]癸/壬-1-烯-4-酮为核心，运用生物电子等排及拼合原理等药物设计方法，设计并合成了14个螺环的联苯磺酰胺类衍生物，测定了它们对AⅡ引起的兔胸主动脉收缩幅度影响的IC50值。结果 所有目标化合物均未见文献报道，其结构经过IR、1H-NMR及MS确证。结论 所设计的化合物均有不同程度的AⅡ受体拮抗活性。     

2-苯氨基咪唑啉-5-酮衍生物的合成及抗肿瘤活性

目的设计并合成新型具有抗肿瘤活性的2-苯氨基咪唑啉-5-酮类化合物。方法以甘氨酸为起始原料,经环合、Knoevenagel缩合、N-烷基化、S-烷基化、取代5步反应合成2-苯氨基咪唑啉-5-酮类衍生物,并初步考察目标物对H460(人肺癌细胞)、HT29(人结肠癌细胞)以及A549(非小细胞肺癌细胞)的增殖抑制活性。结果与结论合成了11个未见文献报道的2-苯氨基咪唑啉-5-酮衍生物,化合物的结构经~1H-NMR、MS谱确证。体外活性测试结果显示,化合物1c、1e表现出较强的抑制细胞增殖活性,其对试验的3种肿瘤细胞的IC_(50)值分别为0.41、0.38(H460),0.41、0.66(HT29),1.44、0.75(A549)μmol·L~(-1),阳性对照药物顺铂(cisplatin)对3种肿瘤细胞的IC50值分别为0.22、0.62、0.35μmol·L~(-1)。初步探讨了目标化合物的构效关系,为进一步结构改造提供参考。     

1-（1，4-苯并二噁烷-2-羰基）-4-取代芳氧烷基哌嗪类α1受体拮抗剂的合成及其生物活性

目的寻找新的1,4-苯并二烷类α1受体拮抗剂。方法选用1,4-苯并二烷为母核,以儿茶酚和取代苯酚为原料,分别经关环、水解、成酰胺、取代、成盐等反应合成目标化合物,并测定该类化合物α1受体拮抗活性。结果与结论设计合成了13个新化合物,结构经ESI-MS、1H-NMR、IR及HR-MS确证。初步药理活性实验表明,其中8个目标化合物的pA2值大于6.00,具有良好的α1受体拮抗活性,有进一步研究的价值。     

1-(1,4-苯并二(口恶)烷-2-羰基)-4-取代芳氧烷基哌嗪类α1受体拮抗剂的合成及其生物活性

目的 寻找新的1,4-苯并二(口恶)烷类α1受体拮抗剂.方法 选用1,4-苯并二(口恶)烷为母核,以儿茶酚和取代苯酚为原料,分别经关环、水解、成酰胺、取代、成盐等反应合成目标化合物,并测定该类化合物α1受体拮抗活性.结果与结论 设计合成了13个新化合物,结构经ESI-MS、1H-NMR、IR及HR-MS确证.初步药理活性实验表明,其中8个目标化合物的pA2值大于6.00,具有良好的α1受体拮抗活性,有进一步研究的价值.     

新型非肽类血管紧张素Ⅱ受体拮抗剂 2．喹唑啉酮和喹唑啉衍生物

本文设计、合成了一系列喹唑啉酮（Ⅳ）和喹唑啉苯氧基苯乙酸类化合物（V），并检测了它们的血管紧张素Ⅱ受体拮抗活动。前文报道了一系列喹啉苯氧基苯乙酸类非肽类血管紧张素Ⅱ受体拮抗剂（Ⅲ），本文以喹唑啉酮代替化合物（Ⅲ）的喹啉获得化合物（Ⅳ），在合成化合物（Ⅳ）时，同时还获得了化合物（V）。但是这两类化合物没有进一步提高活性。在离体试验中（兔胸主动脉环），所有的化合物均显示了竞争性拮抗活性。活性最高的喹唑啉酮（Ⅳb）和喹唑啉（Vb)的pA2值分别为7．0和5．9。     

4-((4-((2-取代苯氧基)乙基)-1-哌嗪)-甲基)-1,2-二氢喹啉-2-酮类化合物的合成及体外α-受体拮抗活性

目的研究DDPH类似物1,2-二氢喹啉-2-酮类化合物的合成及其体外α-受体拮抗活性。方法通过酰化、溴代、环合和取代反应等合成目的物;推测了异常中间体3-溴-4-溴甲基-1,2-二氢喹啉-2-酮(5)和3-溴-4-甲基-1,2-二氢喹啉-2-酮(6)的生成机理;测定目的物的体外α-受体拮抗活性。 结果设计、合成了12个新化合物II_1～6和IV_1～6,其中6个目的物1,2-二氢喹啉-2-酮类(IV_1～6)的结构经IR,¹HNMR,MS和HRMS确证;IV₃,IV₄和IV₆对兔主动脉环抑制作用较明显。结论化合物IV₃,IV₄和IV₆显示了一定的抑制活性,值得进一步研究。     

N-取代-3-吲哚乙酰胺类α1-肾上腺素受体拮抗剂的合成及生物活性

目的设计合成新型吲哚乙酰胺类α1-肾上腺素受体拮抗剂,评价其α1-肾上腺素受体拮抗活性.方法 结合α1-肾上腺素受体拮抗剂的构效关系和计算机辅助药物设计方法所构建的药效团模型,设计合成了19个N-取代-3-吲哚乙酰胺类化合物,并测定拮抗参数pA2值.结果 18个化合物未见文献报道,其结构均经1H-NMR、IR及ESI-MS(HRMS)确证.结论 初步生物活性测试表明:所合成的目标化合物多数具有较好的α1-肾上腺素受体拮抗活性.     

6-(4-酰基-1-哌嗪乙酰氨基)-3,4-二氢-2(1H)-喹啉酮类化合物的合成及正肌力活性初探

目的:寻找具有正性肌力活性的化合物。方法:根据文献报道的二氢喹啉酮类正性肌力药物的结构特点,设计、合成了其类似物。以苯胺为起始原料经多步合成,对所得化合物用离体豚鼠心脏与主动脉观察了心肌收缩力、扩血管作用及心率。结果:合成了1 0个6-( 4-酰基1-哌嗪乙酰氨基)-3 ,4-二氢-2( 1HH) 喹啉酮类化合物( 4a～4j) ,均为未见文献报道的化合物。结论:初步药理试验表明,化合物( 4h)显示了正性肌力及扩血管活性。     

2,5-二芳基-1,3-氧硫戊环化合物的合成及iNOS/PAF双重抑制活性的研究

目的寻找既能抑制iNOS又能拮抗PAF受体的化合物.方法以具有PAF受体拮抗活性的2,4-二芳基-1,3-二硫戊环为先导物,合成其生物电子等排体氧硫戊环化合物,并在其2位芳环上引入具有iNOS抑制活性的基团,测定目标化合物的iNOS抑制活性和PAF受体拮抗活性.结果合成了25个未见文献报道的目标物,其中9个化合物(I2～I7、I10、Ⅱ5、Ⅱ6)的iNOs抑制活性强于正在Ⅲ期临床的iNOS抑制剂氨基胍.PAF受体拮抗活性测试表明,I4活性高于阳性对照药ZH-2,I5活性与ZH-2相当,I 2、I6、I8、I10和Ⅱ5、Ⅱ6活性稍低于ZH-2.结论 I4、I5具有较高的iNOS/PAF双重抑制活性,值得进一步研究.     

3-取代2-吲哚酮类化合物的合成与抗肿瘤活性研究

目的寻找新的具有血管内皮细胞生长因子受体酪氨酸激酶抑制活性的3-取代2-吲哚酮类化合物。方法以2-吲哚酮为原料，利用缩合反应合成目标化合物，并进行体外初步药效学评价。结果设计并合成了5种化合物，其中4种为首次发现，体外初步药效学研究表明，所合成的化合物均具有抑制S-180肿瘤细胞生长的活性，其中化合物Ⅱ活性最强。结论3-取代2-吲哚酮类化合物具有抑制S-180肿瘤细胞生长的活性，化合物中吲哚环平面与相应的芳环平面之间处于垂直状态时活性较强。     

Design, synthesis, structural studies, biological evaluation, and computational simulations of novel potent AT(1) angiotensin II receptor antagonists based on the 4-phenylquinoline structure

Novel AT(1) receptor antagonists bearing substituted 4-phenylquinoline moieties instead of the classical biphenyl fragment were designed and synthesized as the first step of an investigation devoted to the development of new antihypertensive agents and to the understanding of the molecular basis of their pharmacodynamic and pharmacokinetic properties. The newly synthesized compounds were tested for their potential ability to displace [(125)I]Sar(1),Ile(8)-Ang II specifically bound to AT(1) receptor in rat hepatic membranes. These AT(1) receptor binding studies revealed nanomolar affinity in several of the compounds under study. The most potent ligands 4b,t were found to be equipotent with losartan and possessed either a 3-tetrazolylquinoline or a 2-amino-3-quinolinecarboxylic moiety, respectively. Moreover, some selected compounds were evaluated for antagonism of Ang II-induced contraction in rabbit aortic strips, and the most potent compounds in the binding test 4b,t were slightly more potent than losartan in inhibiting Ang II-induced contraction. Finally, the most relevant structure-affinity relationship data were rationalized by means of computational studies performed on the isolated ligands as well as by computational simulations on the ligands complexed with a theoretical AT(1) receptor model.     

含有脂环的三苯乙烯化合物的合成和抗雌激素受体活性的研究

目的　为寻找高效低毒的雌激素受体拮抗剂，设计合成了新结构骨架的三苯乙烯类化合物。方法　通过McMurry反应得到三苯乙烯中间体，再经醚化反应得到目的物。通过抗小鼠子宫增重实验测定化合物的拮抗活性，竞争性结合雌激素受体实验测定化合物对受体的亲和力。结果　本文共合成了35个新化学实体，并利用X-射线晶体衍射和氢谱确定了化合物的构型。结论　所有化合物均能与受体结合(IC₅₀<10^-6mol.L^-1)，其中化合物35与受体的亲和力最大。某些化合物抑制子宫的增长，表现为拮抗作用；有的则促进子宫的增长，表现为激动作用。其中化合物14和27对子宫的抑制作用强于或相当于他莫昔芬，有待进一步研究。     

The chemical syntheses and bioactivities of novel peptide‐based endothelin antagonists

Abstract: Endothelin antagonists, novel tripeptides containing a series of unnatural amino acids, were synthesized and characterized. A linear peptide BQ‐485, perhydroazepin‐1‐yl‐l ‐leucyl (1)‐d ‐tryptophanyl (2)‐d ‐tryptophan (3), was selected as the parent compound. The introduction of d ‐Phe derivatives into these peptidic ET antagonists resulted in potent activity against the contraction of rat aortic smooth muscles induced by ET‐1 (10 nm ) which activated the ET receptors. Among these compounds, 15 tripeptides had high enough antagonistic activity at the level of 10^?7 mol/L (IC₅₀). The activity of three compounds was 10^?6 mol/L (IC₅₀). These HIM‐CO‐Leu‐d ‐Trp‐d ‐Phe(‐R)‐OH compounds as ET_A antagonists may provide a tool for the development of therapeutic agents in the treatment of putative ET‐1‐related disorders.     

腈双吡啉对离体血管舒张的机理

腈双吡啉是从氨利酮与米利酮的合成衍生物中筛选出的强心扩血管药,离体实验表明它能拮抗高K~+、去甲肾上腺素(NE)收缩家兔主动脉环的作用,使NE,CaCl_2的量效曲线右移;在高浓度时降低最大收缩效应。它能增强钙调蛋白拮抗剂拮抗NE引起的家兔主动脉环收缩。结果表明它对NE收缩离体血管的量效曲线不同于选择性阻断α受体的药物妥拉唑啉的作用,也不同于典型的钙拮抗剂维拉帕米的作用,而可能是钙调蛋白的非竞争性拮抗剂。     

查耳酮类化合物对过敏性慢反应物质拮抗作用的构效关系

查耳酮类化合物对过敏性慢反应物质拮抗作用的构效关系何克勤，程桂芳，奚凤德，郭宗儒，朱秀媛（中国医学科学院，中国协和医科大学药物研究所，北京１０００５０）过敏性慢反应物质（ＳＲＳＡ），主要含白三烯Ｃ４（ＬＴＣ４）、白三烯Ｄ４（ＬＴＤ４）和白三烯Ｅ４（Ｌ...     

花生四烯酸、二十碳五烯酸及二十二碳六烯酸对兔主动脉条张力的影响

外源性AA引起兔动脉条收缩,呈剂量依赖性;EPA抑制AA收缩血管亦呈浓度依赖性;DHA对AA收缩血管作用无明显影响。破坏血管内皮后AA收缩血管作用大为减弱,EPA抑制AA收缩血管作用也几乎消失。吲哚美辛能阻断AA收缩兔主动脉条的作用。兔主动脉6-keto-PGF_1α、TXB₂及其比值随AA浓度升高而增加,低剂量EPA对前列腺素类代谢无明显影响,较大剂量时则降低上述指标。     

New selective and potent 5-HT(1B/1D) antagonists: chemistry and pharmacological evaluation of N-piperazinylphenyl biphenylcarboxamides and biphenylsulfonamides

A series of new analogues of N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl] 2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-carboxamide (1; GR127935) as potent and selective 5-HT(1B/1D) antagonists were synthesized and evaluated pharmacologically. Their receptor binding profiles were comparable to that of 1. The 1,3,4-oxadiazole isomer 2 and the 4'-aminocarbonyl and 4'-amidinyl analogues (9 and 10) of 1 had higher affinities at the rat 5-HT(1B) receptor (IC(50) = 0.93, 1. 3, and 0.5 nM, respectively) and calf 5-HT(1D) receptor (IC(50) = 37, 10, and 3 nM, respectively) than did 1 (1.6 and 52 nM for rat 5-HT(1B) and calf 5-HT(1D) receptors, respectively). In the functional in vitro testing of 5-HT(1B/1D) antagonistic properties, 2, 9, 10, 11b (O-demethylated derivative of 2), 13a (O-methylsulfonyl analogue of 2), and 16 (which differs from 2 with a sulfonamide linker) showed more pronounced effects in the K(+)-induced 5-HT release in the cortex of guinea pig than did 1 and 3 (SB224289). Compounds 2, 9, and 10 were equally potent as 1 in rabbit saphenous vein model (pA(2) > 9). A biochemical study of 2 with in vivo microdialysis in the rat brain showed that it is capable of augmenting citalopram (a selective serotonin reuptake inhibitor, SSRI) induced 5-HT release in rat ventral hippocampus, while preventing the decrease in acetylcholine release elicited by citalopram administration. The molecular structure of 2 was determined by single-crystal X-ray analysis. The log P and log D values of these compounds were calculated. This study contributes to the SAR study of N-piperazinylphenyl biphenylcarboxamides as selective and potent 5-HT(1B/1D) antagonists.     

Pinocembrin inhibits angiotensinⅡ-induced vasoconstriction in a Ca~(2+)-dependent and Ca~(2+)-independent manner through blocking AT_1R in the rat aorta

OBJECTIVE To investigate the vasorelaxant effect of pinocembrin(5,7-dihydroxyflavanone),one of the main flavonoids in propolis,on angiotensinⅡ(AngⅡ)induced vasoconstriction and the molecular mechanism of action.METHODS The isometric vascular tone was measured in thoracic aortic rings from SD rat,and the effects of pinocembrin on the single dose and concentration cumulative response curves of AngⅡ were recorded.The binding of pinocembrin to the angiotensin type 1 receptor(AT1R)was studied by using molecule docking analysis.Intracellular[Ca2+]([Ca2+]i)was measured with Fura2/AM in VSMCs.The phosphorylation levels of myosin light chain 2(MLC2)and myosin phosphatase target unit 1(MYPT1),and protein level of Rho kinase 1(ROCK1)in the rat aortic rings were detected by Western blotting.RESULTS Pinocembrin was observed to inhibit AngⅡ-induced vasoconstriction in rat aortic rings with either intact or denuded endothelium.In endothelium-denuded tissues,pinocembrin(pD′2 4.28±0.15)counteracted the contractions evoked by cumulative concentrations of AngⅡ.In a docking model,pinocembrin showed effective binding at the active site of AT1R.Pinocembrin was shown to inhibit both AngⅡ-induced Ca2+ release from internal stores and Ca2+ influx.Moreover,the increase in the phosphorylation of MLC2 and MYPT1,and the increased protein level of ROCK1 induced by AngⅡ was blocked by pinocembrin.CONCLUSION Pinocembrin inhibits AngⅡ-induced rat aortic ring contraction in a Ca2+-dependent and Ca2+-independent manner via blocking AT1R.     

Synthesis and pharmacological evaluation of new pyrazolidine-3, 5-diones as AT(1) angiotensin II receptor antagonists

On the basis of the structure of the non-peptide receptor antagonist irbesartan, a new series of AT(1) ligands was designed. In these compounds the central imidazolone nucleus of irbesartan was replaced by a pyrazolidine-3,5-dione structure. The key intermediate N-alkylpyrazolidine-3,5-diones were synthesized according to a new and general method. The most active compounds possess a spirocyclopentane ring at position 4, a linear butyl chain at position 1, and the [2'-(5-tetrazolyl)biphenyl-4-yl]methyl or [2'-(benzoylaminosulfonyl)biphenyl-4-yl]methyl group at position 2. Affinity toward the AT(1) and AT(2) receptors was assessed by the ability of the compounds to competitively displace [(3)H]AII from its specific binding sites. The most active compounds, 28 and 48, displayed high affinity for the AT(1) receptor, good selectivity AT(1) versus AT(2), and potent in vitro antagonist activity.